You are here

New Fluticasone Furoate/Vilanterol Combo Drug Submitted for FDA Review

GSK and Theravance seek an indication for FF/VI (100/25 mcg) for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

GSK and Theravance are reviewing the strategy for a future U.S. filing for asthma.

FF/VI is one of several respiratory medicines being developed by GSK. Other potential products include the investigational LAMA/LABA combination umeclidinium bromide (UMEC)/VI, VI monotherapy, and MABA (GSK961081), all developed in collaboration with Theravance. GSK is also developing FF monotherapy, UMEC monotherapy, and an anti-IL5 monoclonal antibody (mepolizumab).

Read the news release from GlaxoSmithKline.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs